Meet the 2022 Rising Stars

After a difficult selection process, where many interesting abstracts coming from all over the World have been evaluated, we are delighted to present you the Rising Stars of 9th Edition of the International Workshop on Lung Health.

Dr. Yoon Kyung (Rachel) Chang

Postdoctoral researcher, Sydney Pharmacy School
University of Sydney, Australia

Rising star scientific work:
Inhaled bacteriophage (or phage) therapy has the potential to revolutionise the treatment of respiratory infections caused my multidrug-resistant (MDR) Pseudomonas aeruginosa infections. We have developed novel phage and phage-antibiotic combination formulations for inhaled therapy that can target and kill MDR pathogens in the lungs with promising safety and efficacy profiles in vivo.

Prof. Shital Patil

Consultant in pulmonary and critical care medicine, Pulmonary Medicine
Venaktesh Chest Hospital, Latur Maharshtra India

Rising star scientific work:
Lung fibrosis in Post-covid 19 cases is documented and should be assessed cautiously to have successful treatment outcome. Age above 50 years, male gender, Diabetes, High CT severity, longer duration of illness, proper timing of initiation of BIPAP/NIV therapy, and its early use in comorbid class has documented significant impact on post covid lung fibrosis. Lung fibrosis is known to occur relatively more often in COVID-19 pneumonia cases in presence of hyperglycemia and it will take more than usual time to resolve in presence of Diabetes mellitus. Response to conventional antifibrotics is excellent and it will have positive impact on radiological and clinical outcome in post covid-19 fibrosis cases.

Ms. Efthymia Theofani

PhD candidate, Cellular Immunology Laboratory
Biomedical Research Foundation, Academy of Athens, Greece

Rising star scientific work:
We report an unexplored mechanistic link between impaired TFEB-associated autophagy and excessive NLRP3 signaling that underlies asthma severity. Amelioration of asthma pathogenesis upon TFEB reprogramming, illuminates TFEB as a novel therapeutic target for SA.